{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"description":"A minor response is defined as having achieved \\>25% but less than 50% reduction in serum IgM levels.","groups":[{"description":"Intended therapy consisted of 48 weeks of lenalidomide (25 mg/d for 3 weeks and then 1 week off) along with rituximab (375 mg/m(2)/wk) dosed on weeks 2 to 5 and 13 to 16.","id":"OG000","title":"Lenalidomide and Rituximab"}],"paramType":"NUMBER","populationDescription":"Evaluable patients. 4 participants were withdrawn for adverse events and were unevaluable.","reportingStatus":"POSTED","timeFrame":"34.3 months","title":"Minor Response Rate","type":"SECONDARY","unitOfMeasure":"participants"}